Q3 Earnings Estimate for SNDX Issued By B. Riley

Key Points

• B. Riley forecasts Syndax Pharmaceuticals will report a Q3 2025 EPS of ($0.68), maintaining a "Strong-Buy" rating on the stock.
• The company reported a 984.5% increase in revenue year-over-year for the last quarter, with earnings per share of ($0.83), surpassing analyst estimates.
• Analysts have varied target prices for Syndax Pharmaceuticals, with Citigroup raising their price target from $46 to $51 while maintaining a "buy" rating.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Analysts at B. Riley issued their Q3 2025 earnings estimates for Syndax Pharmaceuticals in a research report issued on Wednesday, August 6th. B. Riley analyst M. Mamtani expects that the company will post earnings per share of ($0.68) for the quarter. B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Syndax Pharmaceuticals' Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.99) EPS, FY2026 earnings at ($1.16) EPS and FY2027 earnings at $0.12 EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $0.18. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The business had revenue of $37.96 million for the quarter, compared to analyst estimates of $26.64 million. During the same quarter in the previous year, the firm posted ($0.80) earnings per share. Syndax Pharmaceuticals's revenue was up 984.5% compared to the same quarter last year.

A number of other equities analysts have also issued reports on SNDX. Citigroup boosted their target price on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the stock a "buy" rating in a research report on Tuesday. Wall Street Zen raised shares of Syndax Pharmaceuticals to a "sell" rating in a research report on Tuesday, May 6th. BTIG Research boosted their target price on shares of Syndax Pharmaceuticals from $43.00 to $56.00 and gave the stock a "buy" rating in a research report on Tuesday. Scotiabank boosted their price target on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a report on Tuesday, May 6th. Finally, Guggenheim reissued a "buy" rating and issued a $32.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $36.91.

Syndax Pharmaceuticals Stock Performance

SNDX stock traded down $0.24 on Friday, reaching $12.48. 2,853,978 shares of the company were exchanged, compared to its average volume of 2,416,729. Syndax Pharmaceuticals has a 12 month low of $8.58 and a 12 month high of $22.50. The stock's fifty day moving average price is $10.08 and its 200 day moving average price is $11.89. The firm has a market capitalization of $1.08 billion, a PE ratio of -3.21 and a beta of 0.74. The company has a debt-to-equity ratio of 2.06, a current ratio of 4.71 and a quick ratio of 5.75.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Quarry LP acquired a new stake in shares of Syndax Pharmaceuticals in the 1st quarter valued at $25,000. Virtus ETF Advisers LLC boosted its stake in shares of Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after purchasing an additional 827 shares in the last quarter. Magnetar Financial LLC acquired a new stake in shares of Syndax Pharmaceuticals in the 1st quarter valued at $132,000. Optimize Financial Inc acquired a new position in Syndax Pharmaceuticals during the 4th quarter worth about $152,000. Finally, Lazard Asset Management LLC acquired a new position in Syndax Pharmaceuticals during the 4th quarter worth about $153,000.

Insider Activity at Syndax Pharmaceuticals

In other news, CEO Michael A. Metzger sold 7,534 shares of the business's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $9.29, for a total value of $69,990.86. Following the sale, the chief executive officer owned 298,661 shares in the company, valued at approximately $2,774,560.69. The trade was a 2.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.10% of the company's stock.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).